Article Details
Retrieved on: 2025-01-05 17:43:12
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses the development of ZT-002 for Metabolic Dysfunction-Associated Steatohepatitis by Beijing QL Biopharmaceutical. It highlights how GlobalData's business intelligence tools assess the drug's phase transition and approval chances, linking to clinical research.
Article found on: www.pharmaceutical-technology.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here